General Information of Drug (ID: DMXH1KC)

Drug Name
CL-316,243 Drug Info
Synonyms
UNII-52H8DB0TKX; 52H8DB0TKX; 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid; CL-316243; 5-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)-1,3-benzodioxole-2,2-dicarboxylic acid; CL 316243; CL316,243; Cl-316243 Free diacid; AC1NUOLQ; Lopac0_000295; SCHEMBL2345491; GTPL3462; CHEMBL1204876; BDBM25763; ZINC1493298; 183720-02-7; 1,3-Benzodioxole-2,2-dicarboxylic acid, 5-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-; LS-187111
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2 [1]
Cross-matching ID
PubChem CID
5312115
CAS Number
CAS 138908-40-4
TTD Drug ID
DMXH1KC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mirabegron DMS1GYT Overactive bladder GC50.0 Approved [4]
Trihexyphenidyl DMB19L8 Dystonia 8A02 Approved [5]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [6]
Bopindolol DMIFYLX Hypertension BA00-BA04 Approved [7]
Mepindolol DMUDWP9 Angina pectoris BA40 Approved [8]
Rimiterol DMA47C6 Asthma CA23 Approved [9]
Bitolterol DMK6XAV Chronic obstructive pulmonary disease CA22 Approved [10]
Nipradilol DMA65ER Angina pectoris BA40 Approved [11]
Vibegron DMFR201 Overactive bladder GC50.0 Approved [12]
ONO-2506 DMCA2PJ Stroke 8B20 Phase 2/3 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NC-2100 DMJKZUC Discovery agent N.A. Investigative [14]
Drug Name Drug ID Indication ICD 11 Highest Status REF
NC-2100 DMJKZUC Discovery agent N.A. Investigative [14]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-3 (ADRB3) TTMXGCW ADRB3_HUMAN Agonist [2]
Mitochondrial uncoupling protein 1 (UCP1) TTI12YJ UCP1_HUMAN Inducer [3]
Mitochondrial uncoupling protein 2 (UCP2) TTSC2YM UCP2_HUMAN Inducer [3]
Mitochondrial uncoupling protein 3 (UCP3) TT12RJK UCP3_HUMAN Inducer [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3462).
2 Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49.
3 Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37.
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
6 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
7 Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
8 Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
9 Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
10 Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
11 Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
13 FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
14 A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes. 2000 May;49(5):759-67.